600998.SS SHH
Jointown Pharmaceutical Group Co., Ltd.
1W: +3.7%
1M: +4.3%
3M: +4.1%
YTD: -3.4%
1Y: -5.6%
3Y: +1.8%
5Y: +3.9%
¥5.05 ($0.75)
+0.09 (+1.81%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
$3.1B
-35.1% ▼
5Y CAGR: +2.2%
Capital Expenditures
$975M
+7.0% ▲
5Y CAGR: -3.9%
Free Cash Flow
$2.1B
-43.0% ▼
5Y CAGR: +6.0%
Dividends Paid
$1.6B
-65.8% ▼
Buybacks
$268M
+86.6% ▲
Net Change in Cash
-$1.0B
-187.8% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $3.4B | $2.6B | $2.3B | $2.3B | $2.8B |
| Depreciation & Amort. | $514M | $657M | $736M | $775M | $857M |
| Stock-Based Comp. | $52M | $80M | $94M | $104M | $0 |
| Change in Working Capital | -$365M | $198M | -$424M | $245M | -$606M |
| Other Non-Cash Items | -$369M | -$249M | $1.6B | $1.4B | $45M |
| Operating Cash Flow | $3.4B | $3.5B | $4.0B | $4.8B | $3.1B |
| — Investing Activities — | |||||
| Capital Expenditures | -$1.5B | -$1.4B | -$1.2B | -$1.0B | -$975M |
| Acquisitions (Net) | -$21M | $9M | -$126M | -$20M | $712M |
| Investment Purchases | -$573M | -$890M | -$541M | -$1.3B | -$907M |
| Investment Sales | $430M | $1.6B | $1.4B | $577M | $296M |
| Other Investing | $346M | -$1.9B | $2.0B | $447M | -$718M |
| Investing Cash Flow | -$1.3B | -$2.5B | $1.5B | -$1.4B | -$1.6B |
| — Financing Activities — | |||||
| Net Debt Issuance | -$1.1B | -$1.8B | -$3.5B | -$350M | -$1.6B |
| Stock Repurchased | -$300M | -$114K | -$426M | -$2.0B | -$268M |
| Dividends Paid | -$738M | -$914M | -$549M | -$937M | -$1.6B |
| Other Financing | $2.0B | $1.5B | $461M | -$950M | $885M |
| Financing Cash Flow | -$184M | -$2.0B | -$4.9B | -$2.2B | -$2.5B |
| Net Change in Cash | $2.0B | -$1.1B | $583M | $1.1B | -$1.0B |
| Cash End of Period | $8.2B | $7.1B | $7.7B | $8.8B | $7.8B |
| Free Cash Flow | $2.0B | $2.1B | $2.7B | $3.7B | $2.1B |